Rodrigues Ana Bento, Rodrigues Anabela, Correia Catarina Jacinto, Jesus Gustavo Nobre, Ribeiro João Miguel
Serviço de Medicina Intensiva, Centro Hospitalar Universitário Lisboa Norte, 1649-028 Lisboa, Portugal.
Clínica Universitária de Medicina Intensiva, Faculdade de Medicina de Lisboa, 1649-028 Lisboa, Portugal.
J Clin Med. 2024 Jan 26;13(3):719. doi: 10.3390/jcm13030719.
(1) Background: Extracorporeal membrane oxygenation (ECMO) is a complex procedure affecting both the risk of thrombosis and bleeding. High-quality data to personalize anticoagulation management in ECMO are lacking, resulting in a high variability in practice among centers. For this reason, we review coagulation methods and monitoring and share a pragmatic proposal of coagulation management, as performed in our high-volume ECMO Referral Centre; (2) Methods: We revised the anticoagulation options and monitoring methods available for coagulation management in ECMO through PubMed search based on words including "anticoagulation," "coagulation assays," "ECMO," "ELSO," and "ISTH"; (3) Results: Actual revision of the literature was described as our routine practice regarding ECMO anticoagulation and monitoring; (4) Conclusions: No coagulation test is exclusively predictive of bleeding or thrombotic risk in patients undergoing ECMO support. An approach that allows for a tailored regimen of anticoagulation (regardless of agent used) and monitoring is mandatory. To accomplish this, we propose that the titration of anticoagulation therapies should include multiple laboratory tests, including anti-Xa, aPTT, ACT, viscoelastic tests, AT levels, platelet count, fibrinogen, and FXIII levels. Anticoagulation regimens should be tailored to a specific patient and personalized based on this complex array of essays.
(1) 背景:体外膜肺氧合(ECMO)是一个复杂的过程,会影响血栓形成和出血风险。缺乏高质量数据来实现ECMO抗凝管理的个性化,导致各中心在实际操作中存在很大差异。因此,我们回顾了凝血方法和监测,并分享了我们大容量ECMO转诊中心实施的凝血管理实用建议;(2) 方法:我们通过PubMed搜索,基于“抗凝”、“凝血检测”、“ECMO”、“ELSO”和“ISTH”等关键词,修订了可用于ECMO凝血管理的抗凝选择和监测方法;(3) 结果:文献的实际修订被描述为我们关于ECMO抗凝和监测的常规做法;(4) 结论:没有一种凝血检测能单独预测接受ECMO支持患者的出血或血栓形成风险。必须采用一种能够制定个性化抗凝方案(无论使用何种药物)和监测的方法。为实现这一点,我们建议抗凝治疗的滴定应包括多项实验室检测,包括抗Xa、活化部分凝血活酶时间(aPTT)、活化凝血时间(ACT)、粘弹性检测、抗凝血酶(AT)水平、血小板计数、纤维蛋白原和因子 XIII水平。抗凝方案应根据特定患者量身定制,并基于这一系列复杂的检测进行个性化调整。